Share Email Print
cover

Proceedings Paper

Interstitial laser irradiation of metastatic mammary tumors in combination with intratumoral injection of immunoadjuvant
Author(s): Chet Joshi; Jessnie Jose; Daniel Figueroa; Jessica Goddard; Xiaosong Li; Hong Liu; Robert E. Nordquist; Tomas Hode; Wei R. Chen
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Laser immunotherapy (LIT) was developed to treat metastatic cancers using a combination of laser irradiation and immunological stimulation. The original design of LIT employs a non-invasive, selective laser photothermal interaction, using an in situ light-absorbing dye. However, this non-invasive treatment mode faces challenges in treating deep, large tumors. Furthermore, it has difficulties in the cases of highly pigmented skin overlying target tumors. To overcome these limitations, interstitial laser immunotherapy (ILIT) was proposed. In ILIT, a cylindrical, side-fire fiber diffuser is placed inside the target tumor to induce thermal damage. To enhance the interstitial irradiation induced photothermal interaction, an immunological modifier, glycated chitosan (GC), is injected into the tumor after the laser treatment. In this study, a cylindrical diffuser with an active length of 1 cm was used to treat tumors of 1 to 1.5 cm in size. Different laser powers (1 to 3 watts) and different irradiation durations (10 to 30 minutes) were used to test the thermal effects of ILIT. Different doses of the GC (1.0%, 0.1 to 0.6 ml per rat) were used to determine the immunological effects of ILIT. Our results show that the animal survival depends on both laser dose and GC dose. A dose of 0.2 ml per tumor appeared to result in the highest survival rate under interstitial laser irradiation with 2.5 watts and 20 minutes. While the results in this study are not conclusive, they indicate that interstitial laser irradiation can be combined with immunotherapy to treat metastatic cancers. Furthermore, our results suggest that an optimal combination of laser dose and GC dose could be obtained for future clinical protocols using interstitial laser immunotherapy.

Paper Details

Date Published: 9 February 2012
PDF: 10 pages
Proc. SPIE 8224, Biophotonics and Immune Responses VII, 822408 (9 February 2012); doi: 10.1117/12.906539
Show Author Affiliations
Chet Joshi, Univ. of Central Oklahoma (United States)
Jessnie Jose, Univ. of Central Oklahoma (United States)
Daniel Figueroa, Univ. of Central Oklahoma (United States)
Jessica Goddard, Univ. of Central Oklahoma (United States)
Xiaosong Li, First Affiliated Hospital of Chinese PLA (China)
Chinese PLA General Hospital (China)
Hong Liu, The Univ. of Oklahoma (United States)
Robert E. Nordquist, Immunophotonics, Inc. (United States)
Tomas Hode, Immunophotonics, Inc. (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)


Published in SPIE Proceedings Vol. 8224:
Biophotonics and Immune Responses VII
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top